FDA panel rejects Allergan's Tazoral

Article

National report - The benefits of Allergan's proposed oral psoriasis drug, Tazoral, do not outweigh possible risks of birth defects and bone loss, a U.S. Food and Drug Administration advisory panel has decided.

Related Videos
Related Content

Phase 3 Trial Data Highlights Efficacy of OnabotulinutoxinA in Platysma Prominence

September 26th 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

POLL: What Strategies Have You Found Most Effective in Managing Alopecia?

September 25th 2023

The Cutaneous Connection: Cosmetic Dermatology: Procedures and Practice

March 17th 2022

Hyaluronic Acid-Based Fillers Effective in Treating Signs of Aging

September 20th 2023

Pointers With Portela: What to Know About Ozempic

September 19th 2023

Phase 3 Trial Data Highlights Efficacy of OnabotulinutoxinA in Platysma Prominence

September 26th 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

POLL: What Strategies Have You Found Most Effective in Managing Alopecia?

September 25th 2023

The Cutaneous Connection: Cosmetic Dermatology: Procedures and Practice

March 17th 2022

Hyaluronic Acid-Based Fillers Effective in Treating Signs of Aging

September 20th 2023

Pointers With Portela: What to Know About Ozempic

September 19th 2023

Phase 3 Trial Data Highlights Efficacy of OnabotulinutoxinA in Platysma Prominence

September 26th 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

POLL: What Strategies Have You Found Most Effective in Managing Alopecia?

September 25th 2023

The Cutaneous Connection: Cosmetic Dermatology: Procedures and Practice

March 17th 2022

Hyaluronic Acid-Based Fillers Effective in Treating Signs of Aging

September 20th 2023

Pointers With Portela: What to Know About Ozempic

September 19th 2023
© 2023 MJH Life Sciences

All rights reserved.